New-onset pemphigus foliaceus following SARS-CoV-2 infection and unmasking multiple sclerosis: A case report

Fatemeh Mohaghegh; Parvaneh Hatami; Arezoo Refaghat; Mohammadjavad Mehdizadeh; Zeinab Aryanian; Nessa Aghazadeh Mohandesi; Zeinab Mohseni Afshar

doi:10.1002/ccr3.5910

New-onset pemphigus foliaceus following SARS-CoV-2 infection and unmasking multiple sclerosis: A case report

Clin Case Rep. 2022 Jun 3;10(6):e05910. doi: 10.1002/ccr3.5910. eCollection 2022 Jun.

Authors

Fatemeh Mohaghegh¹, Parvaneh Hatami², Arezoo Refaghat³, Mohammadjavad Mehdizadeh⁴, Zeinab Aryanian^{2

5}, Nessa Aghazadeh Mohandesi⁶, Zeinab Mohseni Afshar⁷

Affiliations

¹ Department of Dermatology Skin Diseases and Leishmaniasis Research Center Isfahan University of Medical Sciences Isfahan Iran.
² Autoimmune Bullous Diseases Research Center Tehran University of Medical Sciences Tehran Iran.
³ Department of Dermatology Isfahan University of Medical Sciences Isfahan Iran.
⁴ Radiology Department Zahraye Marziyeh Hospital Isfahan Iran.
⁵ Department of Dermatology Babol University of Medical Sciences Babol Iran.
⁶ Department of Dermatology Mayo Clinic Rochester Minnesota USA.
⁷ Clinical Research Development Center Imam Reza Hospital Kermanshah University of Medical Sciences Kermanshah Iran.

Abstract

Development of pemphigus foliaceus (PF) following SARS-CoV-2 infection has only been reported in one patient who had received Bamlanivimab and thus might be considered as a drug-induced case of PF. Here, we reported the first case of PF arising solely after COVID infection without taking any culprit drug.

Keywords: COVID‐19; SARS‐Cov‐2; multiple sclerosis; pemphigus; pemphigus foliaceus; rituximab.

Publication types

Case Reports